WHO ICTRP trial
A multicenter, randomized, double-blind, parallel group, placebo-controlled…
NL-OMON56053 · Overview of Medical Research in the Netherlands (NL-OMON) · Recruiting
Key facts
| Trial ID | NL-OMON56053 |
|---|---|
| Public title | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy |
| Scientific title | A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy - CLNP023B12301 (APPEAR-C3G) |
| Primary sponsor | Novartis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Argentina;Belgium;Brazil;Canada;China;Czechia;France;Germany;Greece;India;Israel;Italy;Japan;Netherlands;Slovakia;Spain;Switzerland;Turkey;United Kingdom;United States of America |
| Conditions | Complement Kidney Disease Nephropathy;10029149;Complement Kidney Disease;Nephropathy |
| Interventions | Adult participants will be randomized to one of the two treatment arms in a 1:1 ratio. • Iptacopan arm: Iptacopan orally at 200 mg b.i.d. for 6 months (double-blind) followed by open-label iptacopan at 200 mg b.i.d. for an additional 6… |
| Registration date | Oct 23, 2023 |
| Target size | 4 |
| Secondary IDs | NL77639.056.21;2020-004589-21;NCT04817618 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: